» Articles » PMID: 25385620

Prediction of Interindividual Differences in Hepatic Functions and Drug Sensitivity by Using Human IPS-derived Hepatocytes

Abstract

Interindividual differences in hepatic metabolism, which are mainly due to genetic polymorphism in its gene, have a large influence on individual drug efficacy and adverse reaction. Hepatocyte-like cells (HLCs) differentiated from human induced pluripotent stem (iPS) cells have the potential to predict interindividual differences in drug metabolism capacity and drug response. However, it remains uncertain whether human iPSC-derived HLCs can reproduce the interindividual difference in hepatic metabolism and drug response. We found that cytochrome P450 (CYP) metabolism capacity and drug responsiveness of the primary human hepatocytes (PHH)-iPS-HLCs were highly correlated with those of PHHs, suggesting that the PHH-iPS-HLCs retained donor-specific CYP metabolism capacity and drug responsiveness. We also demonstrated that the interindividual differences, which are due to the diversity of individual SNPs in the CYP gene, could also be reproduced in PHH-iPS-HLCs. We succeeded in establishing, to our knowledge, the first PHH-iPS-HLC panel that reflects the interindividual differences of hepatic drug-metabolizing capacity and drug responsiveness.

Citing Articles

Standard Protocols for Characterising Primary and In Vitro-Generated Human Hepatocytes.

Heydari Z, Gramignoli R, Piryaei A, Zahmatkesh E, Pooyan P, Seydi H J Cell Mol Med. 2025; 29(3):e70390.

PMID: 39910642 PMC: 11798750. DOI: 10.1111/jcmm.70390.


Development of Liver Cancer Organoids: Reproducing Tumor Microenvironment and Advancing Research for Liver Cancer Treatment.

Li K, Ren K, Du S, Gao X, Yu J Technol Cancer Res Treat. 2024; 23:15330338241285097.

PMID: 39363866 PMC: 11456184. DOI: 10.1177/15330338241285097.


An hepatitis B and D virus infection model using human pluripotent stem cell-derived hepatocytes.

Chi H, Qu B, Prawira A, Richardt T, Maurer L, Hu J EMBO Rep. 2024; 25(10):4311-4336.

PMID: 39232200 PMC: 11466959. DOI: 10.1038/s44319-024-00236-0.


Functional intestinal monolayers from organoids derived from human iPS cells for drug discovery research.

Inui T, Uraya Y, Yokota J, Yamashita T, Kawai K, Okada K Stem Cell Res Ther. 2024; 15(1):57.

PMID: 38424603 PMC: 10905936. DOI: 10.1186/s13287-024-03685-5.


A general fluorescence off/on strategy for fluorogenic probes: Steric repulsion-induced twisted intramolecular charge transfer (sr-TICT).

Hanaoka K, Ikeno T, Iwaki S, Deguchi S, Takayama K, Mizuguchi H Sci Adv. 2024; 10(7):eadi8847.

PMID: 38363840 PMC: 10871538. DOI: 10.1126/sciadv.adi8847.


References
1.
Ingelman-Sundberg M . Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res. 2001; 482(1-2):11-9. DOI: 10.1016/s0027-5107(01)00205-6. View

2.
Takayama K, Nagamoto Y, Mimura N, Tashiro K, Sakurai F, Tachibana M . Long-term self-renewal of human ES/iPS-derived hepatoblast-like cells on human laminin 111-coated dishes. Stem Cell Reports. 2013; 1(4):322-35. PMC: 3849256. DOI: 10.1016/j.stemcr.2013.08.006. View

3.
Bakke O, Manocchia M, de Abajo F, Kaitin K, Lasagna L . Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995; 58(1):108-17. DOI: 10.1016/0009-9236(95)90078-0. View

4.
Spina E, Gitto C, Avenoso A, Campo G, Caputi A, Perucca E . Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol. 1997; 51(5):395-8. DOI: 10.1007/s002280050220. View

5.
Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004; 5(1):6-13. DOI: 10.1038/sj.tpj.6500285. View